ABL Bio will present our BBB shuttle platform 'Grabody-B' as a poster at the CNS Drug Delivery Summit. This poster focuses on the transcytosis pathway of IGF1R, which differentiates it from the existing BBB shuttle, the transferrin receptor, and the mechanism of action of Grabody-B for improving the limitations of CNS therapeutics. ABL Bio aims to become a company that solves the BBB problem of CNS therapeutics through Grabody-B. #CNS #BBB #Shuttle #IGF1R #CNS_Drug_Delivery_Summit
ABL Bio Inc.
생명공학 연구
Gyeonggi-do Seongnam-si 팔로워 1,782명
A global leader in bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases.
소개
ABL Bio Inc. (Kosdaq: 298380) is a South Korean biotechnology company dedicated to the development of bispecific antibody therapeutics to improve and save people's lives. With our BsAb platforms ‘Grabody-T,’ ‘Grabody-I’ and ‘Grabody-B,’ we have built a robust pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated excellent efficacy and safety. We also created a next-generation antibody drug conjugate program to treat various cancers. In the neurodegenerative disorder space, we have developed Grabody-B platform, which is designed to maximize blood-brain barrier (BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. We continue to actively expand and advance our pipeline through global strategic partnerships. For more information, please visit http://ablbio.com
- 웹사이트
-
http://www.ablbio.com/en
ABL Bio Inc. 외부 링크
- 업계
- 생명공학 연구
- 회사 규모
- 직원 51-200명
- 본사
- Gyeonggi-do Seongnam-si
- 유형
- 상장기업
- 설립
- 2016
- 전문 분야
- Biotechnology, Bispecific Antibody, BBB Penetration, Immuno-Oncology, ADC, 4-1BB, neurodegeneration 및 antibody
위치
-
기본
길 보기
16 Daewangpangyo-ro 712 beon-gil, Bundang-gu
KR Gyeonggi-do Seongnam-si 13488
ABL Bio Inc. 직원
업데이트
-
ABL Bio will attend the ‘2024 Pharmaceutical and Bio Industry Innovation Forum’ hosted by the Korea Health Industry Development Institute on November 27th and present its bispecific ADC development strategy. We look forward to meeting healthcare professionals from various fields including industry, academia, and hospitals at this forum and discussing ADC development trends and strategies. #Innovation #Forum #Bispecific_ADC #ADC #KHIDI
-
-
ABL Bio Inc.님이 퍼감
𝐅𝐫𝐨𝐦 𝐒𝐞𝐨𝐮𝐥: Seoul based ABL Bio Inc. is emerging as a leader in bi-specific antibodies - with programs in CNS, oncology, and a unique approach to making ADCs bi-specific as well Founder & CEO Sang Hoon Lee describes the science that sets ABL apart and where he sees Korea biotech headed. Full video: https://lnkd.in/gHSY7xWr BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent | Klein Hersh
-
ABL Bio attended the 16th Protein & Antibody Engineering Summit (PEGS Europe) held in Barcelona, Spain. At this event, our CEO, Sang Hoon Lee did an oral presentation on 4-1BB-based bispecific antibody platform 'Grabody-T'. The title of the presentation is ‘4-1BB T cell Engaging BsAb (Grabody-T) Activated T Cells only in the Tumor Microenvironment and Demonstrated Superior Efficacy and Safety Profile’. It was a very meaningful time to be able to introduce our Grabody-T in front of antibody experts. We will continue to do our best to promote the value of the Grabody-T platform and explore various business opportunities. #PEGSEurope #Protein #Antibody #Bispecific #Platform_technology
-
-
Our ADC team has presented bispecific ADC development strategy at World ADC San Diego 2024. ABL Bio is working hard to achieve our goal of submitting INDs for bispecific ADC pipeline next year. Please give us lots of interest and support 😁 #bispecific #ADC #WorldADC
-
-
ABL Bio will present our bispecific ADC development strategy next week in the World ADC San Diego 2024. Our ADC team participate in this event as a speaker. The title of the presentation is 'Bispecific ADC as Next Generation of ADC may Overcome Current Clinical Limitations.' Please give our team a lot of attention!
-
-
ABL Bio has completed the manufacturing technology transfer for ABL301, a bispecific antibody candidate for the treatment of neurodegenerative diseases including Parkinson’s disease, to Sanofi, and will receive a milestone of $5 million. In January 2022, ABL Bio signed an exclusive collaboration and exclusive worldwide license agreement for ABL301 with Sanofi. Based on our collaboration with Sanofi, ABL Bio will do our best to accelerate the clinical development of ABL301 and contribute to a better life for Parkinson’s disease patients.
-
-
ABL Bio announces clinical collaboration to evaluate ABL103 in combination with KEYTRUDA® (pembrolizumab) in patients with solid tumors. The full press release can be found through the link: https://lnkd.in/gydB-Q-4
-
ABL Bio was selected as the 'Most Promising Biologics Drug' development company at the Korea Biopharma Excellence Awards 2024 hosted by IMAPAC. We are very happy to recieve the award, and believe that this is good opportunity to promote our technology for developing bispecific antibodies and ADC pipeline. Thank you for everyone and ABL Bio will keep focusing on the development of bispecific antibodies and bispecific ADCs.
-